EQS-Adhoc: BB Biotech AG publishes its interim report

Ad hoc announcement pursuant to Art. 53 LR

April 21, 2023

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2023 amounted to CHF 254 mn (loss of CHF 300 mn in the same period 2022). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2023, is available under report.bbbiotech.ch/Q123 or www.bbbiotech.com.

For further information:

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

1612911  21-Apr-2023 CET/CEST